DDInter118 DDInter1376
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Aripiprazole {u} (Compound) resembles {v} (Compound) Nefazodone
Aripiprazole {u} (Compound) resembles {v} (Compound) Trazodone
Aripiprazole {u} (Compound) binds {v} (Gene) ADRA1B
Aripiprazole {u} (Compound) upregulates {v} (Gene) AARS
Aripiprazole {u} (Compound) palliates {v} (Disease) bipolar disorder
Aripiprazole {u} (Compound) downregulates {v} (Gene) PCNA
Aripiprazole {u} (Compound) causes {v} (Side Effect) Orthostatic hypotension
Aripiprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Aripiprazole (Compound) resembles Nefazodone (Compound)
Aripiprazole (Compound) resembles Trazodone (Compound)
Aripiprazole (Compound) binds ADRA1B (Gene)
Aripiprazole (Compound) upregulates AARS (Gene)
Aripiprazole (Compound) palliates bipolar disorder (Disease)
Aripiprazole (Compound) downregulates PCNA (Gene)
Aripiprazole (Compound) causes Orthostatic hypotension (Side Effect)
Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole